Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations selected in HIV-2-infected patients failing a regimen including atazanavir.

The Journal of antimicrobial chemotherapy - 1 Jan 2013

Cavaco-Silva Joana, Aleixo Maria João, Van Laethem Kristel, Faria Domitília, Valadas Emília, Gonçalves Maria de Fátima, Gomes Perpétua, Vandamme Anne-Mieke, Cunha Celso, Camacho Ricardo Jorge

Abstract excerpt

OBJECTIVES: To investigate mutations selected in viruses from HIV-2-infected patients failing a highly active antiretroviral treatment (HAART) regimen including atazanavir/ritonavir. METHODS: Twenty-eight HIV-2-infected patients previously exposed to atazanavir/ritonavir and failing therapy were studied. The protease (PR) gene was amplified and sequenced, and mutations emerging under atazanavir/ritonavir...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to Oligopeptides

Share to Pyridines

Share to Ritonavir

Share to Treatment Failure

Source

Identifiers

PMID: 22977160
DOI: 10.1093/jac/dks363

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations selected in HIV-2-infected patients failing a regimen including atazanavir.PMID 22977160Read ↗

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance MutationsSemantic proximity Read ↗

Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).Semantic proximity Read ↗

Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.Semantic proximity Read ↗

Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.Semantic proximity Read ↗

Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).Semantic proximity Read ↗

Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.Semantic proximity Read ↗

Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.Semantic proximity Read ↗

[Viral resistance and genetic barrier of atazanavir].Semantic proximity Read ↗

Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.Semantic proximity Read ↗

Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.Semantic proximity Read ↗

Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.Semantic proximity Read ↗

Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.